TVM Capital Life Science

TVM Capital Life Science employs a dual-pronged investment strategy that targets innovative life science products. The first prong focuses on financing early-stage therapeutics through a single-asset company approach, leveraging its strategic partnership with Eli Lilly. This model allows the firm to efficiently develop first-in-class or best-in-class differentiated assets. The second prong involves investing in differentiated commercial-stage medical technologies, diagnostics, digital health products, and late-stage therapeutics.

The firm primarily targets sectors with high unmet medical needs, including oncology, immunology, diabetes, CNS/neurodegeneration, pain, cardiovascular diseases, and rare diseases. TVM Capital Life Science invests across various stages, from pre-seed to Series C, with a geographic focus on North America and Europe. The firm seeks to partner with founders who demonstrate a strong vision and capability to lead their companies in the competitive life sciences market.

TVM Capital Life Science has a diverse portfolio of notable companies, including:

• Aurka Pharma Inc.: Developed an aurora kinase A inhibitor and was acquired by Eli Lilly shortly after TVM's investment.
• CoLucid Pharmaceuticals: Focused on a novel migraine treatment, achieved a successful IPO, and was acquired by Eli Lilly for $960 million.
• Acanthas Pharma, Inc.: Developed a small molecule targeting mutations in multiple cancers and was acquired by Eli Lilly.
• AL-S Pharma AG: Focused on developing a compound for ALS patients.
• Ixchelsis Ltd: Developing IX-01 for treating premature ejaculation, which has shown positive clinical proof of concept results.
• Modulate Therapeutics Inc.: Working on a novel immune-oncology nanomedicine.
• Proteon Therapeutics, Inc.: Successfully completed an IPO.
• Probiodrug AG: Also successfully completed an IPO.

Dr. Hubert Birner: Managing Partner with extensive experience in the life sciences sector. He has been instrumental in leading investments in various successful biotech companies.

Stefan Fischer: Managing Partner (Finance) who oversees the financial operations and strategic planning of the firm. He has a strong background in venture capital and finance.

Dr. Luc Marengère: Managing Partner with a focus on investment strategy and portfolio management. He has a deep understanding of the life sciences market.

Dr. Sascha Berger: General Partner who specializes in early-stage investments and has a strong track record in supporting biotech startups.

Dr. Alain Thibault: General Partner with expertise in medical technologies and therapeutics, contributing to the firm's strategic direction.

To pitch to TVM Capital Life Science, startups should send their proposals via email to info@tvm-capital.com. It is essential to include a comprehensive pitch deck that outlines the business model, market opportunity, competitive landscape, and team qualifications. The firm prefers detailed information on the product's development stage and any existing partnerships or collaborations.

Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are beneficial but not mandatory.

TVM Capital Life Science operates the **TVM Life Science Ventures VII** fund, which focuses on single-asset investments aimed at developing pharmaceutical assets to human proof-of-concept efficiently. This fund is designed to support innovative life science companies in their early stages of development.

In 2024, TVM Capital Life Science led a €23 million Series C investment in Smart Reporting, a company specializing in medical reporting technology. Additionally, the firm made an €8 million investment in myo, an elderly-care app, indicating active deployment of capital in innovative life science solutions.

TVM Capital Life Science continues to participate in industry events, including the JP Morgan Healthcare Conference, where they engage with stakeholders in the healthcare and life sciences sectors.